Arcturus TherapeuticsARCT
Market Cap: $557M
About: Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
Employees: 180
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
121% more call options, than puts
Call options by funds: $9.61M | Put options by funds: $4.35M
6% less funds holding
Funds holding: 179 [Q1] → 169 (-10) [Q2]
6.79% less ownership
Funds ownership: 104.36% [Q1] → 97.57% (-6.79%) [Q2]
23% less first-time investments, than exits
New positions opened: 33 | Existing positions closed: 43
31% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 65
33% less capital invested
Capital invested by funds: $948M [Q1] → $640M (-$308M) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Leerink Partners Lili Nsongo 100% 1-year accuracy 1 / 1 met price target | 240%upside $70 | Outperform Initiated | 12 Aug 2024 |
HC Wainwright & Co. Ed Arce 43% 1-year accuracy 60 / 138 met price target | 206%upside $63 | Buy Maintained | 8 Aug 2024 |
HC Wainwright & Co. Ed Arce 43% 1-year accuracy 60 / 138 met price target | 191%upside $60 | Buy Reiterated | 2 Jul 2024 |
Financial journalist opinion
Based on 9 articles about ARCT published over the past 30 days